Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies
暂无分享,去创建一个
[1] Philipp E. Geyer,et al. Profiling the human intestinal environment under physiological conditions , 2023, Nature.
[2] S. Pekkala. Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease , 2023, International journal of molecular sciences.
[3] B. Neuschwander‐Tetri,et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. , 2023, Hepatology.
[4] F. De Filippis,et al. Therapeutic Effects of Butyrate on Pediatric Obesity , 2022, JAMA network open.
[5] A. Kurilshikov,et al. Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome , 2022, Nature Medicine.
[6] V. Tremaroli,et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease , 2022, Nature Medicine.
[7] Franklin L. Nobrega,et al. Gut virome profiling identifies a widespread bacteriophage family associated with metabolic syndrome , 2022, Nature Communications.
[8] V. Tremaroli,et al. Hyperinsulinemia is Highly Associated with Markers of Hepatocytic Senescence in Two Independent Cohorts. , 2022, Diabetes.
[9] J. Bajaj,et al. Promises of microbiome-based therapies. , 2022, Journal of hepatology.
[10] L. Hall,et al. Microbiome-based interventions to modulate gut ecology and the immune system , 2022, Mucosal Immunology.
[11] M. Nieuwdorp,et al. Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases , 2022, Metabolites.
[12] A. Sanyal,et al. Breakthroughs in therapies for NASH and remaining challenges. , 2022, Journal of hepatology.
[13] O. Pedersen,et al. Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease , 2022, Nature Medicine.
[14] F. Bäckhed,et al. The Metabolic Role and Therapeutic Potential of the Microbiome , 2022, Endocrine reviews.
[15] F. Tacke,et al. The fecal mycobiome in non-alcoholic fatty liver disease , 2021, Journal of Hepatology.
[16] S. Daskalopoulou,et al. Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease. , 2021, European heart journal.
[17] B. Schnabl,et al. Bacteriophages and their potential for treatment of gastrointestinal diseases , 2021, Nature Reviews Gastroenterology & Hepatology.
[18] F. Bäckhed,et al. Duodenal Anaerobutyricum soehngenii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study , 2021, Gut.
[19] B. Neuschwander‐Tetri,et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. , 2021, The New England journal of medicine.
[20] J. Long,et al. Sex-Specific Associations between Gut Microbiome and Non-Alcoholic Fatty Liver Disease among Urban Chinese Adults , 2021, Microorganisms.
[21] V. Tremaroli,et al. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. , 2021, European heart journal.
[22] B. Helmink,et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2021, Cell.
[23] Luis Pedro Coelho,et al. Drivers and determinants of strain dynamics following fecal microbiota transplantation , 2021, bioRxiv.
[24] Takuji Yamada,et al. Identification of Faecalibacterium prausnitzii strains for gut microbiome-based intervention in Alzheimer’s-type dementia , 2021, Cell reports. Medicine.
[25] D. Fouts,et al. Intestinal virome and therapeutic potential of bacteriophages in liver disease. , 2021, Journal of hepatology.
[26] Keli Yang,et al. Alterations in the gut virome in obesity and type 2 diabetes mellitus. , 2021, Gastroenterology.
[27] W. D. de Vos,et al. Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future? , 2021, Cell metabolism.
[28] C. Hill,et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics , 2021, Nature Reviews Gastroenterology & Hepatology.
[29] M. Nieuwdorp,et al. Evaluating causality of cellular senescence in non-alcoholic fatty liver disease , 2021, JHEP reports : innovation in hepatology.
[30] B. Zhong,et al. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis , 2021, Lipids in health and disease.
[31] David A. Drew,et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals , 2021, Nature Medicine.
[32] Zhi Chen,et al. A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases , 2021, Annals of translational medicine.
[33] R. Knight,et al. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. , 2020, Cell metabolism.
[34] K. Clément,et al. Gut microbiota-derived metabolites as central regulators in metabolic disorders , 2020, Gut.
[35] E. Zoetendal,et al. Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis , 2020, Hepatology communications.
[36] D. Knights,et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy , 2020, Gut.
[37] F. Bäckhed,et al. Gut microbial metabolites as multi-kingdom intermediates , 2020, Nature reviews. Microbiology.
[38] H. Herrema,et al. Intestinal microbial metabolites in human metabolism and type 2 diabetes , 2020, Diabetologia.
[39] K. Reddy,et al. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute on Chronic Liver Failure and Death in Patients With Cirrhosis. , 2020, Gastroenterology.
[40] F. Tacke,et al. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. , 2020, Gastroenterology.
[41] V. Tremaroli,et al. Distinct differences in gut microbial composition and functional potential from lean to morbidly obese subjects , 2020, Journal of internal medicine.
[42] Z. Taranu,et al. Challenges of Studying the Human Virome - Relevant Emerging Technologies. , 2020, Trends in microbiology.
[43] R. Knight,et al. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. , 2020, Cell metabolism.
[44] A. Basson,et al. Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease , 2020, Translational Research.
[45] J. Raes,et al. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses , 2020, Nature Microbiology.
[46] C. McKenzie,et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. , 2020, The American journal of gastroenterology.
[47] H. El‐Serag,et al. Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[48] H. Tilg,et al. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications , 2020, Gut.
[49] K. Clément,et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders , 2020, Nature Reviews Gastroenterology & Hepatology.
[50] Oliver Fiehn,et al. A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors , 2020, Cell.
[51] David F Wilson,et al. Ethanol metabolism: The good, the bad, and the ugly. , 2020, Medical hypotheses.
[52] L. Hodson,et al. Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management. , 2019, Endocrine reviews.
[53] Mengwei Xiao,et al. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease , 2019, Gastroenterology research and practice.
[54] A. Kurilshikov,et al. Studying the gut virome in the metagenomic era: challenges and perspectives , 2019, BMC Biology.
[55] Doheon Lee,et al. Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals , 2019, Scientific Reports.
[56] R. Bataller,et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease , 2019, Nature.
[57] Ruifu Yang,et al. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. , 2019, Cell metabolism.
[58] M. Manns,et al. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. , 2019, The lancet. Gastroenterology & hepatology.
[59] S. Taleb. Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases , 2019, Front. Immunol..
[60] J. Venter,et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. , 2019, Cell metabolism.
[61] Jacob M. Luber,et al. The Landscape of Genetic Content in the Gut and Oral Human Microbiome. , 2019, Cell host & microbe.
[62] I. Martínez,et al. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non‐digestible carbohydrates into short‐chain fatty acids , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[63] J. González-Navajas,et al. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[64] T. Hendrikx,et al. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation , 2019, Journal of internal medicine.
[65] S. Handley,et al. Phages and Human Health: More Than Idle Hitchhikers , 2019, Viruses.
[66] Seong-Ah Kim,et al. Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome. , 2019, Research in microbiology.
[67] K. Rioux,et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial , 2019, European Journal of Nutrition.
[68] Evgeni Levin,et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time , 2019, Gut.
[69] J. Raes,et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study , 2019, Nature Medicine.
[70] R. Knight,et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease , 2019, Nature Communications.
[71] B. Colsch,et al. Orchestration of Tryptophan‐Kynurenine Pathway, Acute Decompensation, and Acute‐on‐Chronic Liver Failure in Cirrhosis , 2019, Hepatology.
[72] A. Basit,et al. A four‐strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro , 2019, International journal of pharmaceutics.
[73] T. Vatanen,et al. The Super-Donor Phenomenon in Fecal Microbiota Transplantation , 2019, Front. Cell. Infect. Microbiol..
[74] Wen Zhang,et al. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis , 2019, Therapeutic advances in gastroenterology.
[75] K. Bittinger,et al. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. , 2018, Gastroenterology.
[76] O. Fiehn,et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice , 2018, Gut.
[77] G. Bergström,et al. Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1 , 2018, Cell.
[78] T. Nolin,et al. Gut Colonization with Methanogenic Archaea Lowers Plasma Trimethylamine N-oxide Concentrations in Apolipoprotein e−/− Mice , 2018, Scientific Reports.
[79] Rohit Loomba,et al. Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD , 2018, Hepatology.
[80] Itai Sharon,et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features , 2018, Cell.
[81] V. Tremaroli,et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography , 2018, Nature Medicine.
[82] H. Cortez‐Pinto,et al. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. , 2018, Journal of hepatology.
[83] P. Gentileschi,et al. Molecular Phenomics and Metagenomics of Hepatic Steatosis in Non-Diabetic Obese Women , 2018, Nature Medicine.
[84] M. Nieuwdorp,et al. Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans , 2018, Endocrine reviews.
[85] E. Zoetendal,et al. Effect of Vegan Fecal Microbiota Transplantation on Carnitine‐ and Choline‐Derived Trimethylamine‐N‐Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome , 2018, Journal of the American Heart Association.
[86] Chenli Liu,et al. A human gut phage catalog correlates the gut phageome with type 2 diabetes , 2018, Microbiome.
[87] Rohit Kohli,et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids , 2018, Hepatology.
[88] Y. Koyama,et al. Intestinal fungi contribute to development of alcoholic liver disease , 2017, The Journal of clinical investigation.
[89] Glenn R. Gibson,et al. The International Scientific Association for Probiotics and Prebiotics ( ISAPP ) consensus statement on the definition and scope of prebiotics , 2018 .
[90] P. Hylemon,et al. Fungal dysbiosis in cirrhosis , 2017, Gut.
[91] J. Holst,et al. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial , 2017, Scientific Reports.
[92] C. Hill,et al. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics , 2017, Nature Microbiology.
[93] U. Deuschle,et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. , 2017, Journal of hepatology.
[94] Xiaokang Wu,et al. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia , 2017, Scientific Reports.
[95] Ruifu Yang,et al. Safety Evaluation of a Novel Strain of Bacteroides fragilis , 2017, Front. Microbiol..
[96] V. Young. The role of the microbiome in human health and disease: an introduction for clinicians , 2017, British Medical Journal.
[97] P. Dawson,et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives , 2016, Hepatology.
[98] E. Zoetendal,et al. Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial. , 2016, Cell metabolism.
[99] Hanns-Ulrich Marschall,et al. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. , 2016, Cell metabolism.
[100] T. Drake,et al. Sex differences and hormonal effects on gut microbiota composition in mice , 2016, Gut microbes.
[101] Morris A. Swertz,et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity , 2016, Science.
[102] Lawrence A. David,et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota , 2016, Hepatology.
[103] W. Bockelmann,et al. Ethanol Production by Selected Intestinal Microorganisms and Lactic Acid Bacteria Growing under Different Nutritional Conditions , 2016, Front. Microbiol..
[104] Ron Milo,et al. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans , 2016, Cell.
[105] C. Dejong,et al. Hepatic Uptake of Rectally Administered Butyrate Prevents an Increase in Systemic Butyrate Concentrations in Humans. , 2015, The Journal of nutrition.
[106] Josivan G. Lima,et al. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? - A mechanistic hypothesis. , 2015 .
[107] J. Spence,et al. Importance of sex and gender in atherosclerosis and cardiovascular disease. , 2015, Atherosclerosis.
[108] N. Lane. The unseen world: reflections on Leeuwenhoek (1677) ‘Concerning little animals’ , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[109] J. March,et al. Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes , 2015, Diabetes.
[110] Glenn R. Gibson,et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .
[111] Johannes Gescher,et al. Bioengineering and Biotechnology Review Article Metabolic Engineering of Escherichia Coli for Production of Mixed-acid Fermentation End Products , 2022 .
[112] Rafal S. Sobota,et al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease , 2014, Proceedings of the National Academy of Sciences.
[113] Mathieu Almeida,et al. Dietary intervention impact on gut microbial gene richness , 2013, Nature.
[114] P. Edwards,et al. Pleiotropic roles of bile acids in metabolism. , 2013, Cell metabolism.
[115] H. Nittono,et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. , 2013, Journal of Hepatology.
[116] S. Hazen,et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. , 2013, The New England journal of medicine.
[117] A. Urbanska,et al. Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B Golden Syrian Hamsters , 2013, PloS one.
[118] A. Hevener,et al. The role of estrogens in control of energy balance and glucose homeostasis. , 2013, Endocrine reviews.
[119] Leah M. Feazel,et al. Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity , 2013, Science.
[120] Lixin Zhu,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.
[121] E. Zoetendal,et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.
[122] E. Zoetendal,et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. , 2012, Gastroenterology.
[123] R. Curi,et al. Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. , 2012, American journal of physiology. Endocrinology and metabolism.
[124] M. Mitrović,et al. Endogenous ethanol production in patients with diabetes mellitus as a medicolegal problem. , 2012, Forensic science international.
[125] M. Uribe,et al. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. , 2010, Annals of hepatology.
[126] S. Cuzzocrea,et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. , 2009, The Journal of nutrition.
[127] Vanessa S Teaberry,et al. Similarities and Differences in the Pathogenesis of Alcoholic and Nonalcoholic Steatohepatitis , 2009, Seminars in liver disease.
[128] G. Macfarlane,et al. Review article: prebiotics in the gastrointestinal tract , 2006, Alimentary pharmacology & therapeutics.
[129] N. Delzenne,et al. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study , 2005, European Journal of Clinical Nutrition.
[130] L. Fernández-Salazar,et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. , 2004, Diabetes care.
[131] J. Busserolles,et al. Oligofructose protects against the hypertriglyceridemic and pro-oxidative effects of a high fructose diet in rats. , 2003, The Journal of nutrition.
[132] A. Neyrinck,et al. Inulin and oligofructose modulate lipid metabolism in animals: review of biochemical events and future prospects , 2002, British Journal of Nutrition.
[133] R. Demeure,et al. Dietary fructans, but not cellulose, decrease triglyceride accumulation in the liver of obese Zucker fa/fa rats. , 2002, The Journal of nutrition.
[134] T. Risby,et al. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. , 2000, Gastroenterology.
[135] Masahiro Tohkin,et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.
[136] G R Gibson,et al. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. , 1995, The Journal of nutrition.
[137] H. Krebs,et al. The physiological role of liver alcohol dehydrogenase. , 1970, The Biochemical journal.
[138] A. Canbay,et al. The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids. , 2018, Annals of hepatology.
[139] William Tottey,et al. Archaebiotics Proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease , 2019 .
[140] V. Pubul,et al. and Cardiovascular Disease: What to , 2019 .
[141] A. Neish,et al. REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY Microbes in Gastrointestinal Health and Disease , 2009 .